Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments.

Current opinion in oncology - 1 Nov 2024

Valenza Carmine, Marsicano Renato Maria, Trapani Dario, Curigliano Giuseppe

Abstract excerpt

PURPOSE OF REVIEW: Patients with advanced breast cancer (aBC) treated with PARP inhibitors (PARPi) can eventually experience disease progression for emerging treatment resistance. This review aims to depict the treatment the molecular landscape, and the innovative therapies for patients with PARPi-resistant BRCA-mutated aBC. RECENT FINDINGS: No specific therapy is specifically available in the setting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 39246166
DOI: 10.1097/CCO.0000000000001092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments.PMID 39246166Read ↗

Facing inevitable PARPis resistance: Mechanisms and therapeutic strategies for breast cancer treatmentSemantic proximity Read ↗

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic ApproachesSemantic proximity Read ↗

Therapeutic advances and application of PARP inhibitors in breast cancerSemantic proximity Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

PARP inhibitors in the management of breast cancer: current data and future prospects.Semantic proximity Read ↗

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.Semantic proximity Read ↗

PARP Inhibitors in Breast and Ovarian CancerSemantic proximity Read ↗

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and ResistanceSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

PARP inhibitors and their evolving role in breast cancer.Semantic proximity Read ↗

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical LandscapeSemantic proximity Read ↗

PARP inhibitors: clinical development, emerging differences, and the current therapeutic issuesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.